Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.

J Biol Chem. 2012 Aug 10;287(33):28087-98. doi: 10.1074/jbc.M112.377218. Epub 2012 Jun 22.

2.

FGFR3 targeting strategies for achondroplasia.

Laederich MB, Horton WA.

Expert Rev Mol Med. 2012 Jan 19;14:e11. doi: 10.1017/erm.2012.4. Review.

PMID:
22559284
3.

Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Foldynova-Trantirkova S, Wilcox WR, Krejci P.

Hum Mutat. 2012 Jan;33(1):29-41. doi: 10.1002/humu.21636. Epub 2011 Nov 16. Review.

4.

Oncogenic FGFR3 gene fusions in bladder cancer.

Williams SV, Hurst CD, Knowles MA.

Hum Mol Genet. 2013 Feb 15;22(4):795-803. doi: 10.1093/hmg/dds486. Epub 2012 Nov 21.

5.

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.

Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR, Cook SJ.

Oncogene. 2013 Jun 20;32(25):3059-70. doi: 10.1038/onc.2012.319. Epub 2012 Aug 6.

PMID:
22869148
6.

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.

Scuto A, Krejci P, Popplewell L, Wu J, Wang Y, Kujawski M, Kowolik C, Xin H, Chen L, Wang Y, Kretzner L, Yu H, Wilcox WR, Yen Y, Forman S, Jove R.

Leukemia. 2011 Mar;25(3):538-50. doi: 10.1038/leu.2010.289. Epub 2010 Dec 17.

7.

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.

Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA.

Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103.

8.

The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FF, Nykter M, Zhang W.

J Clin Invest. 2013 Feb;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9.

9.

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J.

Cancer Res. 2012 Nov 15;72(22):5843-55. doi: 10.1158/0008-5472.CAN-12-1329. Epub 2012 Sep 26.

10.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
11.

Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study.

Amaral AF, Méndez-Pertuz M, Muñoz A, Silverman DT, Allory Y, Kogevinas M, Lloreta J, Rothman N, Carrato A, Rivas del Fresno M, Real FX, Malats N; Spanish Bladder Cancer/EPICURO Study investigators..

J Natl Cancer Inst. 2012 Dec 19;104(24):1897-904. doi: 10.1093/jnci/djs444. Epub 2012 Oct 29.

12.

Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.

Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Öberg Å, Van Guelpen B, Rutegård J, Stenling R, Palmqvist R.

Am J Pathol. 2011 Mar;178(3):1387-94. doi: 10.1016/j.ajpath.2010.12.008.

13.

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC.

PLoS One. 2010 Nov 3;5(11):e13821. doi: 10.1371/journal.pone.0013821.

14.

Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.

Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L.

Am J Hum Genet. 2012 Dec 7;91(6):1108-14. doi: 10.1016/j.ajhg.2012.10.014. Epub 2012 Nov 29.

15.

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL.

Blood. 1998 Nov 1;92(9):3025-34.

16.

Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.

He L, Serrano C, Niphadkar N, Shobnam N, Hristova K.

PLoS One. 2012;7(4):e34808. doi: 10.1371/journal.pone.0034808. Epub 2012 Apr 18.

17.

Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ.

Cell. 1994 Jul 29;78(2):335-42.

PMID:
7913883
18.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.

19.
20.

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K, Okada M.

Oncogene. 2011 Aug 11;30(32):3489-501. doi: 10.1038/onc.2011.63. Epub 2011 Mar 7.

PMID:
21383697

Supplemental Content

Support Center